SR Medical expects HK$68 million-HK$73 million H1 loss, swings from year-ago profit

• SR Medical Technology expects a shareholder-attributable loss of HK$68 million to HK$73 million for the six months ended June 30, 2026.
• That compares with a shareholder-attributable profit of about HK$2.1 million in the prior-year period.
• Higher other operating costs of about HK$75.2 million drove the swing, partly offset by revenue rising about HK$52.2 million.
• Finance costs increased about HK$29.3 million; employee benefit expenses rose about HK$19.2 million.
• Revenue growth reflected the Beijing Chunyu Tianxia Software acquisition, also full operation of the Culver City project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SR Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299810), on August 26, 2026, and is solely responsible for the information contained therein.